What Anafranil Retard Treats: Main Uses and Benefits

Anafranil Retard (Clomipramine) is commonly used to help with several complex mental health and neurological conditions.

The medicine is relevant for managing Major Depressive Disorder, Obsessive-Compulsive Disorder (OCD), and specific obsessional and phobic states. It is also applied in situations involving certain distressing symptoms beyond mood disorders, such as Cataplexy associated with narcolepsy, and may be part of symptomatic management for certain forms of chronic pain. This range of uses covers conditions characterized by periods of heightened symptoms or episodic manifestations.

This formulation helps address symptom clusters that may become intense or disruptive, such as recurrent, intrusive thoughts and profound low mood. The sustained-release action is often used during phases when symptoms become more noticeable, providing supportive relief that may help patients cope more steadily with symptom fluctuations. This supportive role contributes to easing the overall symptom load in conditions marked by heightened physiological stress.

---

Quick Fact: Relief for Obsessive and Compulsive Symptoms Anafranil Retard is relevant in contexts marked by increased discomfort due to the cyclic nature of obsessions and compulsions, and is applied across domains where additional symptomatic support is needed.

Regulatory References

1. Health Products Regulatory Authority Product Information

Eligibility Scope

The eligibility profile for Anafranil Retard (Clomipramine) is determined by official regulatory bodies, setting clear boundaries for use. Individuals are contraindicated if they possess known hypersensitivity to clomipramine or related dibenzazepine tricyclic antidepressants, are in the acute recovery phase of a myocardial infarction, or are taking a Monoamine Oxidase Inhibitor (MAOI).

Category	Eligibility Status & Restriction
Absolute Contraindications	Use is strictly prohibited in patients with severe hepatic or severe renal disease and in those with Congenital long QT syndrome.
Age-Related Restrictions	Safety has not been established for children under 10, though use is approved for OCD in patients aged 10 and older. Use in older adults requires special caution.
Physiological Status	Use is generally not recommended during pregnancy (Category C) or lactation due to the drug's excretion into human milk.
Conditional Use	Caution is required for patients with a history of seizures, pre-existing cardiovascular disease, narrow-angle glaucoma, or moderate organ impairment.

Anafranil Retard (clomipramine) may interact with many other medicines by affecting how the body processes them (pharmacokinetic interaction) or by having similar effects (pharmacodynamic interaction).

Do Not Combine:

• Monoamine Oxidase Inhibitors (MAOIs): Combining clomipramine with an MAOI is strictly forbidden and can cause a serious reaction, including high fever, seizures, and coma. A two-week washout period is required between stopping one of these medicines and starting the other. The washout period after stopping fluoxetine before starting clomipramine is five weeks.

Use with Caution and Monitoring:

• Serotonin-Increasing Medicines: Other drugs that increase serotonin, such as Selective Serotonin Reuptake Inhibitors (SSRIs, e.g., fluoxetine, fluvoxamine), lithium, triptans, and St. John's Wort, must be used with caution due to an increased risk of Serotonin Syndrome.
• Heart Rhythm-Affecting Medicines: Medicines known to prolong the QTc interval (a measure of heart rhythm) should be avoided due to the increased risk of dangerous arrhythmias when combined with clomipramine.
• CYP Enzyme Inhibitors/Inducers: Clomipramine is broken down by specific liver enzymes (CYP450). Medicines that block these enzymes (e.g., cimetidine, fluvoxamine) can increase clomipramine levels and toxicity, while medicines that speed up these enzymes (e.g., phenobarbital, phenytoin) can decrease clomipramine's effect.
• Central Nervous System (CNS) Depressants: Alcohol and other CNS depressants (e.g., sedatives, tranquilizers, some pain medicines) can increase the risk of drowsiness, dizziness, and decreased alertness.
• Anticoagulants: As clomipramine is highly bound to plasma proteins, it may affect the levels of other protein-bound drugs, such as warfarin, requiring careful monitoring.

How Anafranil Retard Works

Dual Modulation of Serotonin and Norepinephrine Systems

Anafranil Retard's mechanism of action is primarily defined by the inhibition of the reuptake transporters for serotonin (5-HT) and norepinephrine (NE). Clomipramine, the parent compound, targets the Serotonin Transporter ( SERT), while its metabolite, desmethylclomipramine, targets the Norepinephrine Transporter ( NET). This inhibition prevents the rapid clearance of 5-HT and NE from the synaptic cleft, increasing their concentration and duration of action on postsynaptic receptors. This molecular effect alters signaling dynamics within central monoaminergic pathways.

Non-Specific Receptor Antagonism

The drug also exhibits antagonism at several non-target receptors, notably the muscarinic cholinergic ( M1), histaminergic ( H1), and alpha1-adrenergic receptors. This secondary activity, through receptor blockade, produces a set of peripheral and central physiological consequences. These include anticholinergic effects (such as reduced parasympathetic signaling) and central depression (via H1 blockade), which are inherent consequences of the drug’s mechanistic profile.

Anafranil Retard (Clomipramine) is administered solely via the oral route, utilizing the sustained-release tablet formulation. The physical form of this medicine dictates that it must be swallowed whole with a sufficient quantity of fluid and must not be crushed or chewed. Altering the tablet structure compromises the controlled delivery system, which is engineered to release the active substance steadily over a prolonged period. This formulation is generally scheduled for once daily (OD) administration, often taken in the evening or at bedtime, and may be taken with or after food.

---

Usage begins with a low starting dose, typically between 25 mg and 50 mg per day for adults, as part of a gradual dose titration process. This initial phase is conducted to establish the effective maintenance dose, which commonly ranges from 50 mg to 75 mg per day. The official maximum recommended daily dose for adults is 150 mg.

---

Dosing protocols require specific adjustments for special populations. For older adults, the starting dosage is substantially reduced (e.g., 10 mg daily), and the target maintenance dose is lower, typically limited to 30 mg to 50 mg per day. The medication is used as part of a long-term therapeutic plan, and official instructions mandate that discontinuation necessitates a slow dose reduction (tapering) process to conclude the course of treatment.

Research Evidence Overview of Studies for Anafranil Retard

This introductory section provides context on the formal clinical evaluation of Anafranil Retard (Clomipramine). The research base primarily consists of established randomized controlled trials (RCTs), where people are randomly assigned to receive the medicine or a comparison, alongside broader systematic reviews and meta-analyses that combine data from multiple trials. This body of research provides context for the medicine’s clinical evaluation.

---

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

Research has explored Clomipramine in studies focusing on Obsessive-Compulsive Disorder (OCD), a condition characterized by fluctuating or episodic manifestations. The evidence includes multicenter placebo-controlled trials which tracked patient-reported outcomes using scales like the Yale-Brown Obsessive-Compulsive Scale (YBOCS) over defined time intervals. These studies reported measured outcomes in the active treatment group compared to the comparison group. A research limitation is that the evidence relies primarily on short-term follow-up durations, meaning long-term effects are not fully established. Furthermore, study reports have noted patient discontinuations from the research.

---

Evidence for Use in Major Depressive Disorder (MDD)

Clomipramine was studied for the management of Major Depressive Disorder (MDD). The research landscape includes historical controlled trials and various studies that monitored the medicine against other tricyclic antidepressants and later-generation treatments. Studies utilized clinical scales, such as the Hamilton Depression Rating Scale (HAMD), to track how symptoms evolved in the observed populations during the acute treatment phase (typically 4 to 6 weeks). A key research limitation is that the primary evidence base supporting this use is largely historical, pre-dating many modern trial standards.

---

Long-Term Studies and Follow-up Durations

Regulatory research includes both short-term acute treatment phases and dedicated intermediate-term follow-up studies to assess the potential for symptom return. However, a primary research limitation across all indications is that long-term effects are not fully established, and there is limited information that tracks patient status over many years following treatment initiation. The available data primarily focuses on short-to-medium-term outcomes.

Key Studies & References

1. The clinical effect of clomipramine in chronic idiopathic pain disorder revisited using the Spielberger State Anxiety Symptom Scale (SSASS) as outcome scale

Common questions about Anafranil Retard (FAQ)

---

Q: Is Anafranil Retard the same as regular clomipramine, or is there a difference?

Anafranil Retard is a specific sustained-release formulation of clomipramine. According to official product information, this means the tablet is engineered to gradually release the active ingredient over many hours. This mechanism is different from standard, immediate-release forms of clomipramine.

---

Q: What are the main health conditions Anafranil Retard is officially approved to treat?

Regulatory bodies have approved this medicine to treat conditions such as Obsessive-Compulsive Disorder (OCD). Depending on the region, it may also be officially indicated for Major Depressive Disorder (MDD) and panic disorders. The official therapeutic indications are always listed in the regulatory labeling.

---

Q: How does the slow-release formulation affect the time the medicine takes to work?

The primary design goal of the sustained-release (Retard) formulation is to ensure a consistent concentration of the drug is maintained in the body throughout the day. This controlled delivery system is intended to support a steady therapeutic effect over time, rather than a rapid, sharp increase in levels.

---

Q: Can Anafranil Retard affect a person's normal sleep schedule or patterns?

Official drug documents list somnolence (or increased sleepiness) as a very common side effect. Other sleep disturbances, such as insomnia, are also documented as potential effects. This is a common point addressed in the adverse reactions section of the labeling.

---

Q: What types of over-the-counter medicines should be checked for potential interaction with Anafranil Retard?

Official prescribing information advises caution with over-the-counter products that fall into specific drug classes. These include medicines classified as Central Nervous System (CNS) depressants or those known to increase serotonin levels, such as certain cold remedies.

---

Q: Are there any specific foods or supplements known to have interactions with Anafranil Retard?

The interaction section in the regulatory documents notes caution with the herbal supplement St. John's Wort, which can increase the risk of side effects related to high serotonin levels. Specific major food interactions are generally not highlighted in the core official documentation.

---

Q: What is the main perceived difference between Anafranil Retard and a typical SSRI antidepressant?

Anafranil Retard belongs to the class of tricyclic antidepressants (TCAs) and is described as a dual modulator, meaning it affects both serotonin and norepinephrine systems. Typical Selective Serotonin Reuptake Inhibitors (SSRIs), in contrast, are primarily designed to target only the serotonin system.

---

Q: Does Anafranil Retard cause physical dependence or have specific withdrawal symptoms when stopping?

Regulatory documents emphasize that discontinuation of the medicine is typically managed using a slow dose reduction (tapering) process. This is required to help minimize the possibility of experiencing withdrawal symptoms, which may include nausea, vomiting, or anxiety.

---

Q: Where can a person find the full, official prescribing information for Anafranil Retard?

The complete, official prescribing information for the medicine is made publicly available online by regulatory bodies. You can typically find these materials, including Patient Information Leaflets, on websites for agencies like the FDA (DailyMed) or the European Medicines Agency (EMA).

---

Q: Is it common to experience a change in appetite after starting this medication?

The official safety profile lists weight gain as a common side effect of the medicine. This may be an indirect indication of changes in appetite or metabolic function, but the specific term 'change in appetite' is generally not used in the formal safety summary.

---

Q: Are there generic versions of clomipramine available that are comparable to Anafranil Retard?

While generic versions of clomipramine are available, they may not necessarily be the specific sustained-release ('Retard') formulation. The verification of whether a generic sustained-release product is comparable to the brand-name formulation is determined by national drug registries.

---

Q: What is the general relationship between Anafranil Retard and driving or operating machinery?

Due to potential side effects like somnolence (sleepiness), dizziness, and blurred vision, regulatory documents typically carry a warning. This advisory indicates that the ability to drive or operate complex machinery may be impaired while taking the medicine.

---

Q: Can Anafranil Retard be used if a person also has epilepsy?

Official safety documents indicate that a history of seizures or conditions that may predispose a person to seizures requires caution in the medicine's prescribing. This is due to the medicine's known potential to lower the seizure threshold.

---

Q: How long does it usually take for a person to notice an effect from Anafranil Retard?

Studies and official information indicate that an initial symptomatic response may typically be observed in the first two to three weeks of treatment. However, the full therapeutic benefit may require a longer period of time to fully develop.

---

Q: Are there official patient guides or educational resources available for Anafranil Retard?

Yes, regulatory agencies require that official, accessible educational materials be created alongside the prescribing information. These typically include a Patient Information Leaflet (PIL) or consumer summaries, designed to provide general drug facts to the public.

---

Q: Can Anafranil Retard be used for anxiety conditions that are not its officially approved indication?

The officially approved indications for any medicine are defined by regulatory agencies based on established clinical trial evidence. Any use for a condition outside of the defined indications listed in the labeling is not part of the official drug's use scope.

---

Q: What are the general facts about what happens if a person forgets to take a dose of Anafranil Retard?

Official patient instructions usually provide guidance regarding missed doses, describing a general protocol. This protocol typically covers what to do if a dose is missed, such as a process for taking the dose when remembered, or skipping it if it is nearly time for the next dose.

---

Q: What kind of general medical monitoring is usually recommended when a person starts Anafranil Retard?

Due to potential effects on the cardiovascular system, regulatory documents recommend specific monitoring when starting treatment. This typically includes checking blood pressure and performing an ECG (electrocardiogram) before or during the early phase of treatment.

---

Q: What should a person generally look out for as signs of an allergic reaction to Anafranil Retard?

Official documents describe signs of a severe allergic reaction (hypersensitivity) to clomipramine. These signs can include rashes, difficulty breathing, and swelling of the face, tongue, or throat. Hypersensitivity is listed as an absolute contraindication.

---

Q: Is it common or necessary to have blood work done while taking Anafranil Retard?

Due to potential effects on the liver and blood counts, official warnings suggest that periodic blood tests may be recommended during long-term treatment. These tests are used to monitor liver function and blood cell counts.

---

Q: Is Anafranil Retard used for pain management, or is that an off-label use?

The officially approved indications for the medicine are defined by regulatory agencies based on established clinical trial evidence. Any use for a condition outside of the defined indications listed in the labeling is not part of the official drug's use scope.

---

Q: What is the half-life of clomipramine and its main active metabolite, according to pharmacology texts?

The half-life, a pharmacological measure of time, is documented in the prescribing information. The half-life of clomipramine itself is generally documented as approximately 21 hours, while that of its main active metabolite is noted to be significantly longer.

---

Q: Is the 'Retard' formulation designed to reduce the severity of side effects?

The primary design goal of the sustained-release (Retard) formulation is to provide a more consistent level of the active substance in the body. While this consistency can help avoid the high peak concentrations that may be associated with some side effects, its stated goal is ensuring steady pharmacological action.

How to Store and Dispose of Anafranil Retard: Regulatory Requirements

Official regulatory documents define strict storage and disposal requirements for Anafranil Retard (clomipramine).

Storage Conditions

Requirement	Official Regulatory Statement
Temperature	Store at a controlled room temperature (e.g., typically below 25 C or 30 C).
Protection	Keep in the original, tightly closed container; protect from moisture and light.
Child Safety	Keep out of the sight and reach of children (mandatory instruction).
Stability	Do not use after the expiration date printed on the packaging.

Disposal Protocol

To dispose of unused or expired Anafranil Retard, do not flush the medication down a toilet or pour it down a sink. The required method is to return it to a drug take-back program or an authorized collection point. If a take-back program is unavailable, the product must be mixed with an undesirable substance (such as used coffee grounds or cat litter) and sealed in a bag for disposal in household trash, according to official government guidance.